Seppe Segers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Seppe Segers has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Heidi Mertes
Bioethics Institute Ghent, Department of Philosophy and Moral Science, Ghent University, Ghent, Belgium
11 shared publications - Michiel De Proost
Bioethics Institute Ghent, Department of Philosophy and Moral Sciences, Ghent University, Ghent, Belgium
10 shared publications - Guido Pennings
Department of Philosophy and Moral Science, Ghent University, Ghent, Belgium
7 shared publications - Brandon Ferlito
Department of Philosophy and Moral Sciences, Bioethics Institute Ghent, Ghent University, Ghent, Belgium
4 shared publications - Dorian Accoe
Department of Philosophy and Moral Science, Ghent University, Ghent, Belgium
4 shared publications - Elizabeth Chloe Romanis
Durham University
2 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Springer Nature in Monash Bioethics Review
- p. 1-19
Power, privilege and moral responsibility: learning from I.M. Young's Social Connection Model in the context of AI-driven healthcare
Artificial intelligence (AI) in healthcare is assumed to introduce risks that are not easily addressed by dominant philosophical models for thinking about responsibility. When an AI tool makes an error that results in patient harm, the question of who is responsible is rarely straightforward. Dominant models of responsibility work when harm can be traced to a single actor, but they fail in socio-technical systems where decisions and actions are distributed across multiple human and technological agents. Iris Marion Young’s social connection model of responsibility offers a systematic way to rethink responsibility in these contexts. Rather than locating responsibility solely after harms occur, Young proposes a forward-looking account that attaches responsibility to those who participate in and benefit from the structural processes that produce harm. Young’s framework organised around parameters of reasoning—power, privilege, interest, collective ability, and personal connection— provides an alternative way for understanding differentiated responsibilities across core actors in AI-driven healthcare.
- 7 August 2026
- Published by Springer Nature in Monash Bioethics Review
- p. 1-19
Open AccessPower, privilege and moral responsibility: learning from I.M. Young's Social Connection Model in the context of AI-driven healthcare
Artificial intelligence (AI) in healthcare is assumed to introduce risks that are not easily addressed by dominant philosophical models for thinking about responsibility. When an AI tool makes an error that results in patient harm, the question of who is responsible is rarely straightforward. Dominant models of responsibility work when harm can be traced to a single actor, but they fail in socio-technical systems where decisions and actions are distributed across multiple human and technological agents. Iris Marion Young’s social connection model of responsibility offers a systematic way to rethink responsibility in these contexts. Rather than locating responsibility solely after harms occur, Young proposes a forward-looking account that attaches responsibility to those who participate in and benefit from the structural processes that produce harm. Young’s framework organised around parameters of reasoning—power, privilege, interest, collective ability, and personal connection— provides an alternative way for understanding differentiated responsibilities across core actors in AI-driven healthcare.
- 5 July 2026
- Published by Taylor & Francis
- p. 41-56
Mortality, Morbidity and Speculation: Ethical Considerations About the Lever for Ectogestation
- 5 July 2026
- Published by Taylor & Francis
- p. 41-56
Mortality, Morbidity and Speculation: Ethical Considerations About the Lever for Ectogestation
- 26 June 2026
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 32 (3)
Proceedings of the first European Ovary Workshop (EOW 2025), Lagos, Portugal, 17–20 February 2025
The inaugural European Ovary Workshop (EOW 2025), that was held on 17–20 February 2025, in Lagos, Portugal, brought together 165 scientists, clinicians, and early career researchers from 28 countries to advance ovarian biology from fundamental mechanisms to clinical translation. The program featured 12 scientific sessions, 17 keynote lectures, 15 selected short talks, 89 flash talks, and >90 posters spanning meiosis, folliculogenesis, ovarian reserve, aging, microenvironment, bioengineering, fertility preservation, environmental toxicology, wildlife conservation, patient-public involvement in science, and ethics. A comprehensive networking program combined formal and informal activities to stimulate scientific exchange and interaction across disciplines and career stages. Post-workshop feedback (n = 86) reflected high satisfaction with scientific content (rated 4.6/5), speaker quality (4.7/5), and networking (4.4/5), while identifying opportunities to expand clinical topics, diversify model organisms, and improve poster logistics. EOW 2025 established a unique community and a biennial platform to accelerate discovery and translation in ovarian research.
- 26 June 2026
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 32 (3)
Proceedings of the first European Ovary Workshop (EOW 2025), Lagos, Portugal, 17–20 February 2025
The inaugural European Ovary Workshop (EOW 2025), that was held on 17–20 February 2025, in Lagos, Portugal, brought together 165 scientists, clinicians, and early career researchers from 28 countries to advance ovarian biology from fundamental mechanisms to clinical translation. The program featured 12 scientific sessions, 17 keynote lectures, 15 selected short talks, 89 flash talks, and >90 posters spanning meiosis, folliculogenesis, ovarian reserve, aging, microenvironment, bioengineering, fertility preservation, environmental toxicology, wildlife conservation, patient-public involvement in science, and ethics. A comprehensive networking program combined formal and informal activities to stimulate scientific exchange and interaction across disciplines and career stages. Post-workshop feedback (n = 86) reflected high satisfaction with scientific content (rated 4.6/5), speaker quality (4.7/5), and networking (4.4/5), while identifying opportunities to expand clinical topics, diversify model organisms, and improve poster logistics. EOW 2025 established a unique community and a biennial platform to accelerate discovery and translation in ovarian research.
- 18 May 2026
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 26 (6) , 39-41
Shaking Up Environmental Justice: Making a Case for Epistemic Sustainability
- 18 May 2026
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 26 (6) , 39-41
Shaking Up Environmental Justice: Making a Case for Epistemic Sustainability
- Open Access
- 1 April 2026
- Published by BMJ in JME Practical Bioethics
- Vol. 2 (2) , e000185
Problem of patient trust and sustainability: a care ethics response to Armitage
- 1 April 2026
- Published by BMJ in JME Practical Bioethics
- Vol. 2 (2) , e000185
Open AccessProblem of patient trust and sustainability: a care ethics response to Armitage
The Anger Paradox: How Angry Should Physicians Be?
This article starts from the question: how angry should physicians be? Since the literature so far has mostly focused on patient anger, we endeavor to turn bioethical attention to physician anger instead. After specifying our central question in four different ways—in terms of its normativity, its use of the term “physicians,” the implied patient‐directed nature of this anger, and the difference between feeling and behaving angrily—we posit the anger paradox (AP) to help guide our argument. We discuss whether anger might damage the therapeutic relationship, or whether it could be a necessary expression of care. We follow three steps in looking at whether physicians can feel, should feel, or should express anger. We complicate the question of care and its objects by introducing Frankfurt's distinction between first‐ and second‐order desires. Finally, we look at the distinction between apt and appropriate anger, concluding that while physician anger can sometimes be apt, it is never appropriate to express toward patients.
The Anger Paradox: How Angry Should Physicians Be?
This article starts from the question: how angry should physicians be? Since the literature so far has mostly focused on patient anger, we endeavor to turn bioethical attention to physician anger instead. After specifying our central question in four different ways—in terms of its normativity, its use of the term “physicians,” the implied patient‐directed nature of this anger, and the difference between feeling and behaving angrily—we posit the anger paradox (AP) to help guide our argument. We discuss whether anger might damage the therapeutic relationship, or whether it could be a necessary expression of care. We follow three steps in looking at whether physicians can feel, should feel, or should express anger. We complicate the question of care and its objects by introducing Frankfurt's distinction between first‐ and second‐order desires. Finally, we look at the distinction between apt and appropriate anger, concluding that while physician anger can sometimes be apt, it is never appropriate to express toward patients.
- 24 August 2025
- Published by BMJ in Journal of Medical Ethics
- Vol. 51 (12) , 807-808
Trapped in the promising role of digital twins?
- 24 August 2025
- Published by BMJ in Journal of Medical Ethics
- Vol. 51 (12) , 807-808
Trapped in the promising role of digital twins?
- 15 July 2025
- Published by Springer Nature in Monash Bioethics Review
- Vol. 44 (1) , 1-10
Speculation as an argument: artificial placenta technology, clinical translation, and the ethical debate about the ethical debate
Researchers developing artificial amnion and placenta technology (AAPT) regard this endeavor as one to enhance outcomes in neonatal intensive care units (NICU), by reducing mortality and morbidity for extremely premature neonates. While other applications can be imagined and have been the topic of ethical debate, there is discontent about bioethical considerations of potential AAPT applications beyond NICU praxis. Dismissed as ‘speculative’, the latter allegedly cloud ‘real’ ethical work necessary for clinical translation. This trope requires ethical attention, since it goes to the heart of bioethical praxis as an effort of studying emerging technologies like AAPT, and as a critical enterprise tethering ethical contemplation to empirics and uncovering value-ladenness of empirical ‘facts’. We explore different functions of speculation in ethics, after which we examine the main criticisms against the purported speculative implementation of AAPT. We then address how defining a practice as speculative reveals more about research priorities and biases, than about some quality of the practice. Labeling scenarios as ‘speculative’ seems to function as an argument in and of itself, rather than that an argument is provided for labeling certain scenarios as speculative, and why this matters. More: the ‘speculation argument’ can be extended to the translational aims of AAPT, its potential risks, and the assumed ‘benefits’ in terms of mortality and morbidity. Projections about ‘morbidity’ and ‘quality of life’ that do not start from insights and experiences of members of the disability community are precisely the type of speculation that should be questioned from a critical ethics perspective.
- 15 July 2025
- Published by Springer Nature in Monash Bioethics Review
- Vol. 44 (1) , 1-10
Speculation as an argument: artificial placenta technology, clinical translation, and the ethical debate about the ethical debate
Researchers developing artificial amnion and placenta technology (AAPT) regard this endeavor as one to enhance outcomes in neonatal intensive care units (NICU), by reducing mortality and morbidity for extremely premature neonates. While other applications can be imagined and have been the topic of ethical debate, there is discontent about bioethical considerations of potential AAPT applications beyond NICU praxis. Dismissed as ‘speculative’, the latter allegedly cloud ‘real’ ethical work necessary for clinical translation. This trope requires ethical attention, since it goes to the heart of bioethical praxis as an effort of studying emerging technologies like AAPT, and as a critical enterprise tethering ethical contemplation to empirics and uncovering value-ladenness of empirical ‘facts’. We explore different functions of speculation in ethics, after which we examine the main criticisms against the purported speculative implementation of AAPT. We then address how defining a practice as speculative reveals more about research priorities and biases, than about some quality of the practice. Labeling scenarios as ‘speculative’ seems to function as an argument in and of itself, rather than that an argument is provided for labeling certain scenarios as speculative, and why this matters. More: the ‘speculation argument’ can be extended to the translational aims of AAPT, its potential risks, and the assumed ‘benefits’ in terms of mortality and morbidity. Projections about ‘morbidity’ and ‘quality of life’ that do not start from insights and experiences of members of the disability community are precisely the type of speculation that should be questioned from a critical ethics perspective.
- Open Access
- 2 July 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (9) , 1605-1615
Stem cell-derived gametes: what to expect when expecting their clinical introduction
Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect—and investors to anticipate—the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including—but not limited to—safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.
- 2 July 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (9) , 1605-1615
Open AccessStem cell-derived gametes: what to expect when expecting their clinical introduction
Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect—and investors to anticipate—the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including—but not limited to—safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.